Artera, a Los Altos, California-based developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, raised $90M in funding.
The round was led by Coatue, Johnson & Johnson Innovation, Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, The Factory and 11 angel investors including Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, and Michael Driscoll.
The company intends to use the funds to invest in the development of tests to support therapy personalization in other cancers.
Led by CEO Andre Esteva, Artera is a precision medicine company developing AI tests to personalize therapy for cancer patients. Its flagship test is the ArteraAI Prostate Test, the first test to predict therapy benefit in localized prostate cancer. It is clinically available through a CLIA-certified laboratory in Jacksonville, Florida, and can be ordered online at artera.ai.
FinSMEs
21/03/2023